| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
XSJ81 (0.35-40 μM, 48 h) significantly inhibited the proliferation of ampullary carcinoma (AC) DPC-X3 cells, with an IC50 of 0.655 μM[1]. XSJ81 (0.35-1.4 μM, 48 h) reduced the EdU fluorescence intensity in DPC-X3 cells in a dose-dependent manner[1]. XSJ81 (0.003-0.011 μM, 2 weeks) inhibited the colony formation of DPC-X3 cells in a dose-dependent manner[1]. XSJ81 (0.35-1.4 μM, 24-48 h) arrested DPC-X3 cells in the G2/M phase, induced dose-dependent apoptosis, and inhibited the migration of DPC-X3 cells[1]. XSJ81 (0.35-1.4 μM, 24 h) induced dose-dependent γ-H2AX foci formation in the nuclei of DPC-X3 cells [1]. XSJ81 (200-500 μM, 30 min) blocked the relaxation effect of Topo I on supercoiled pBR322 plasmid DNA, kept the plasmid in a supercoiled state, and promoted the proteasome degradation of Topo I protein [1]. XSJ81 (100-1000 nM, 0-72 h) induced time- and dose-dependent cytotoxicity in adenoid cystic carcinoma organoids (ACOs) [1].
|
|---|---|
| ln Vivo |
XSJ81 (100 mg/kg, gavage, single spray, 3–14 days) was graft-free in 6-week-old female BALB/c mice[1]. XSJ81 (5–10 mg/kg, intraperitoneal, once every 48 hours for 14 days) showed significant antitumor activity in nude mice with DPC-X3 xenografts[1].
|
| Cell Assay |
Cell Cycle Analysis[1]
Cell Types: DPC-X3 cells Tested Concentrations: 0.35, 0.7, 1.4 μM Incubation Duration: 24 h Experimental Results: Down-regulated S-phase marker CCNA1. Up-regulated G0/G1-phase regulators CNE1 and P53. Apoptosis Analysis[1] Cell Types: DPC-X3 cells Tested Concentrations: 0.35, 0.7, 1.4 μM Incubation Duration: 48 h Experimental Results: Induced dose-dependent apoptosis in DPC-X3 cells. Up-regulated pro-apoptotic protein BAX. Down-regulated anti-apoptotic protein Bcl-2. |
| Animal Protocol |
Animal/Disease Models: DPC-X3 cellular suspensions were subcutaneously injected into the right axillary of the nude mice through orthotopic transplantation procedure to construct the DPC-X3 xenograft model[1]
Doses: 5 mg/kg and 10 mg/kg Route of Administration: i.p., once every 48 h, 14 days Experimental Results: Achieved significant tumor growth inhibition. Showed no significant changes in body weight. Induced extensive apoptotic areas in tumor tissues. |
| References |
| Molecular Formula |
C30H28N4O8S
|
|---|---|
| Molecular Weight |
604.63
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6539 mL | 8.2695 mL | 16.5390 mL | |
| 5 mM | 0.3308 mL | 1.6539 mL | 3.3078 mL | |
| 10 mM | 0.1654 mL | 0.8270 mL | 1.6539 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
